About
4.65USD-0.11 -2.21%
Closed • Updated at 16:38 GMT+00:00Market Cap$1.62B
Volume1.00M
Beta1.71
RSI49.36
Gross Margin89.40%
Nuvation Bio Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 27 2026
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
May 27 2026
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
May 13 2026
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
May 6 2026
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
May 4 2026
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Recent Videos

Nuvation Bio's Ibtrozi Revenue Potential Analyzed
Apr 19, 2026

$NUVB Deep Dive
Apr 19, 2026

Nuvation Bio CRO Sells $904K in Stock, Reduces Direct Holdings by 79%
Apr 14, 2026

How to Invest in Nuvation Bio Inc (NUVB) Step by Step
Mar 17, 2026
Community Chat
Ask AI
Try asking
